Publicacións en colaboración con investigadores/as de Hospital Xeral Calde (21)

2014

  1. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

    BMC Cancer, Vol. 14, Núm. 1

  2. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

    Tumori, Vol. 100, Núm. 2, pp. 225-231

  3. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 160-166

  4. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: A multi-center phase II study

    Anticancer Research, Vol. 34, Núm. 4, pp. 1959-1966

2012

  1. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396

  2. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

    Anti-Cancer Drugs, Vol. 23, Núm. 2, pp. 239-246

2011

  1. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: Results from a phase II study

    Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 686-691

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

  2. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer

    Chemotherapy, Vol. 56, Núm. 2, pp. 142-146

2009

  1. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 2, pp. 379-384

2008

  1. Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer

    Clinical and Translational Oncology, Vol. 10, Núm. 11, pp. 739-744

  2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

2007

  1. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: A phase II study of the Galician Lung Cancer Group (GGCP 013-02)

    Anti-Cancer Drugs, Vol. 18, Núm. 10, pp. 1201-1206

  2. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: A lung cancer Galician group phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 60, Núm. 5, pp. 725-732

  3. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

  4. Gliomatosis cerebri: Diagnóstico y tratamiento con temozolomida, a propósito de un caso

    Oncologia, Vol. 30, Núm. 3, pp. 41-45

2006

  1. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212

2005

  1. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial

    Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 433-438

2003

  1. Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: A multicentre study of galician-lung-cancer-group

    Lung Cancer, Vol. 40, Núm. 2, pp. 215-220

  2. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051